PDA

View Full Version : Ceasar's Palace


Pages : [1] 2
  1. Going Back to the Premium!
  2. The 20-40 Miracle Patient from the Perspective of a Real 20-400 Patient!... The Blind can See!
  3. Something Ventured History of Silicon Valley
  4. I am closing "Ceasar's Palace" and I will keep and maintain, "Ceasar's Palace - Premium"
  5. Maybe it is time to close "Ceasar's Palace"?
  6. Happy Thanksgiving to All!
  7. Have you guys/dolls noticed that ACTC has Morphed into 4 Companies?
  8. #3 Comments on ACTC's CC Today 11/8/12 - More Details on MMD and RS and Uplist
  9. # 1 - Comments on ACTC's CC Today 11/8/12
  10. So... Is there any reason why ACTC should not use their RPEs on a Wet AMD Trial?
  11. So UCL, Coffey, Cirm, and Pfizer wants to know who has an approved patent on Scaffolded RPEs?
  12. Investment Letter #1
  13. Just Listen to Lanza's Podcast from March and feel his excitement! LOL
  14. Regenerative Patch Technologies--Coffey & Lebowski working together?
  15. How Many Partners for Novartis?
  16. The Probability that Pfizer or Anybody Else can discover a Work Around ACTC's Patent is ...
  17. Practical Analysis of Pfizer's Presentation and Lanza's Presentation!
  18. The Geo-Political Imperative of Oil and Natural Gas in the Next 10 Years
  19. Remember the BetaMax Vs. VHS Battle?
  20. Now... Lets do a Political and Machiavellian Analysis of What Pfizer is Doing with Coffey's Trial
  21. A More Strategic and Practical Analysis of the recent Bainbridge and Coffey Talk at UTube!
  22. And Now... What would Rabin's best Strategic Move for ACTC's JV?
  23. Professor James Bainbridge, consultant surgeon at Moorfields and Chair of Retinal Studies at University College London.
  24. Now... Will it Make Perfect Sense for Pfizer to License ACTC's RPEs for Wet AMD?
  25. Will it make sense for ACTC to License RPE Cells to Pfizer on Wet AMD?
  26. Is it Possible that Pfizer will get their cGMP Clinical Grade RPEs for the UK Trials from ACTC?
  27. Now... Pfizer's Wet AMD Trials makes more sense!
  28. Analysis of a Possible Pfizer Vs. ACTC Infringement Case
  29. 2006 Patent Infringement Lawsuit by ACTC!
  30. The Nobel Prize and Competition, Politics, and IP Defense Strategy
  31. Pfizer and Yamanaka!
  32. Congrats to Dr. Yamanaka for his Nobel prize. We hope to file with the FDA to translate iPS cells into the clinic in the next few months.
  33. Analysis of a Possible Pfizer Vs. ACTC Infringement Case
  34. The Evolution of ACTC
  35. ACTC's Patent Coverage, Strategy, and Future Court Cases
  36. The Only Other Possible Company Making or can Make Contract RPE Cells ... is Lonza
  37. So If you are the President of Genentech, and you get the JV with ACTC...
  38. What exactly is the License Agreement betweenUniversity College London and Pfizer?
  39. Where in the World will Pfizer get their Clinical Grade cGMP RPE Cells?
  40. Another Key Rabin Sentence that got Stuck in my Head!
  41. The Rodman and Renshaw September Presentation is an Outline for a Board Presentation to Roche!
  42. Rodman and Renshaw, September 3012 - Rabin's Sales Pitch!
  43. Vincent's "Double Blockbuster Quote"!
  44. Private Messages
  45. Holmes is Back!
  46. The Strategic Imperatives for Roche and Novartis
  47. Access to the Premium
  48. # 2 Aerin... Here is a Systems Look at Rabin's Latest Blog!
  49. #2 Q&A at the Premium
  50. Q&A at the Premium ...
  51. Icing on the Cake! LOL! The world is upside down!
  52. How Large is the Wound Healing Market?
  53. #3 Analyis of Big Cat's Seeking Alpha's Rabin Interview
  54. #2 Analyis of Big Cat's Seeking Alpha's Rabin Interview
  55. #1 Analyis of Big Cat's Seeking Alpha's Rabin Interview
  56. ACTC's Core Competency and Its Long Term Corporate Strategy
  57. The Strategic Reasons for Partnering MSC's Early
  58. Nature is all about Symmetry and Simplicity ... that is why the China JV Bothers me! (Premium 7/12)
  59. Seeking Alpha interview with GR
  60. 100,000 Cell Patient
  61. #2 Merck -Serono and ACTC's Potential
  62. Merck -Serono and ACTC's Potential
  63. Glaucoma next IND? Reply to Invest Post at ICell
  64. So How do we analyze the ACTC JV Chess Board at this time?
  65. Speculative Analysis!
  66. Three JV Models that ACTC may use...
  67. Tracking Merck KGaA footprints ... Very Interesting
  68. A Question of Ocular Strategy
  69. Today's 22% jump!
  70. Just Got Back from Chicago Late Morning Today
  71. I woke up this morning and my first thought is : We have a horse race!
  72. Potential Combination Ocular Therapy with RPEs
  73. Insider Trading and Quiet Period
  74. Living our Normal Lives and our Investment on ACTC
  75. Novartis is alsoworking on MSC's and MS via Opexa
  76. A personal request
  77. Ann Romney has MS
  78. Navigation to Ceasar's Palace Premium
  79. READ and FOLLOW-No Further Warnings will be Given.
  80. I just formed a group called - Ceasar's Palace - Premium
  81. Question via Private Message ...
  82. Cure
  83. Conversation with my Grand Kids about the use of Words!
  84. I would like to comment on Matt Vincent's statement about our posters/great detectives...
  85. Editorial Comment on Ceasar's Palace before I end the Day!
  86. One more Big Wow for ACTC's MSCs!!!!!
  87. Bio-Int. June Presentation - The Most Robust, Aggressive, and Dominant Presentation Ever!
  88. Comments on Vincent's Blow by Blow via Feeed's Reporting
  89. ACT vs Yamanaka's iPS Platform
  90. This Article will give you a sense why Lanza's MSCs will Break the Industry!
  91. Spent a few hours today checking up all the data we have from the Science, to Finance and Marketing!
  92. ACTC's NPCs and the Human Brain!
  93. Now Let us Focus on ACTC's MSC Plans for the Eyes!
  94. The Great Battles of History and ACTC vs. Medical and Religious Traditions
  95. Osiris - Genzyme Agreement
  96. #1 Critical Skill Sets of a Successful Regenerative Medicine/Stem Cell Company
  97. Weekend Reading: I talked about this several months ago as it applies to ACTC!
  98. What exactly is the meaning of a "super potent stem cell" used by Dr. Lanza?
  99. Comment on Lanza's Interview on Coast to Coast with George Noory
  100. #2 The Global Economic Risk that all of Us are Facing!
  101. ACTC vs GERN ... a Competitive Analysis!
  102. #1 The Global Economic Risk that all of Us are Facing!
  103. #1 How will the FDA's Regenerative Medicine approval process evolve in the next 5 years or so?
  104. Great Sunny Day in Northen California and Key Focus on ICell and the Palace!
  105. Editorial Comment on ICell and the Role of "Ceasar's Palace"
  106. Editorial Comment on the SEC Case and Rabin's Performance
  107. Reply to Skipball on SEC Issue covered on another thread!
  108. ACTC's Product Pipeline vs. Genentech's Wish List!
  109. What is coming out of left-field? And moving very fast!
  110. ACTC's iPSCs Master Cell Bank, Blood Derivatives, and Cancer
  111. #4 Rabin's Newest Presentation in the UK - Huge Therapeutic Ocular Development - Page 22
  112. All About Facebook!
  113. #3 Rabin's Newest Presentation in the UK
  114. #2 Rabin's Newest Presentation in the UK
  115. #1 Rabin's Newest Presentation in the UK
  116. And here is something more Wicked and than just simply growing old! LOL!
  117. And here is something more wicked than Cardio and Heart Attack!
  118. And here is another "Wicked One" for Lanza's Mesenchymal Cells!
  119. If you think MS is Big as a Prochymal Application? Think Again!
  120. No Company can Compete with ACTC in Ophthalmology... in the long term!
  121. Short Reminder to All... Please///
  122. Osiris' Prochymals are adult stem cells! Lanza's Team must be Smiling Ear to Ear!
  123. #1 Packaging the JV ... is appearing to be a Key Consideration for ACTC
  124. Lose Threads around ACTC's JV Posture and some arguments at ICell...
  125. Focusing on Strategic Issues... and Why?
  126. CIRM MMD filings.. Interesting, Check this out!
  127. #2 1Q 2012 ACTC Conference Call - Lessons Learned
  128. 1Q 2012 ACTC Conference Call - Lessons Learned
  129. #3 Why Build the 2 Stem Cell Banks, Why the stronger focus on NPCs and MSCs?
  130. Paradigm Shift and its Impact on the Drug Industry and Regenerative Medicine
  131. What if ACTC were put on the Auction Block???
  132. #2 Why Build the 2 Stem Cell Banks, Why the stronger focus on NPCs and MSCs?
  133. #1 Why Build the 2 Stem Cell Banks, Why the stronger focus on NPCs and MSCs?
  134. Where Exactly are We (ACTC)?
  135. #1 China JV - Off the cuff Comments
  136. Some of my off the cuff comments ...
  137. There are Traders here at ICell... trying very hard to push down the PPS
  138. #2 Top of the Head threads Vs. Page by Page Review of ACTC's Annual Presentation
  139. #1 Top of the Head threads Vs. Page by Page Review of ACTC's Annual Presentation
  140. Stem Cell Investment Strategy
  141. #7 ACTC's Incredible World Class Presentation ... Congratulations to Rabin
  142. #6 ACTC's Incredible World Class Presentation ... Congratulations to Rabin
  143. #5 ACTC's Incredible World Class Presentation ... Congratulations to Rabin
  144. #4 ACTC's Incredible World Class Presentation ... Congratulations to Rabin
  145. #3 ACTC's Incredible World Class Presentation ... Congratulations to Rabin
  146. # 2 ACTC's Incredible World Class Presentation ... Congratulations to Rabin
  147. # 1 ACTC's Incredible World Class Presentation ... Congratulations to Rabin
  148. I think we need UPDATE from Ceasar's what he thinks about the Presentation???
  149. Is ACTC a Hill or a Towering Mt. Everest?
  150. Wondering if Ceasar has any opinion on S/h Meeting topics?
  151. BioPharma's Patent Cliff - Further Discussion via LV Matador
  152. #2 Anthony Adamis , VP of Global Opthalmology Division of Genentech is in deep shit!
  153. Anthony Adamis , VP of Global Opthalmology Division of Genentech is in deep shit!
  154. 2012 Science Festival Winner, Documentary "Stem Cell Revolutions"
  155. Will it make sense to propose a Combination Therapy Using RPE Cells and Lucentis for Wet AMD?
  156. And, By the way Novartis has a licensing agreement with ACTC from 10+ years ago...
  157. Ignoring or Not Understanding the Potential of ACTC's Patent Portfolio
  158. Political Stance and Future
  159. Comment's on the coming Annual Meeting Agenda
  160. Roslin Revenue
  161. The Cell Level Software and the Ability of Progenitor Cells for Self Assembly
  162. Biotech companies will be facing particular ethical challenges as their products enter the marketplace.
  163. Objective, Subjective, Pessimist, Optimist... Classical labels that has no practical meaning when Investing
  164. The Case Against Many Posters Desire for Insider Buying of ACTC Stocks!
  165. Looking at an ACTC JV from a BioPharma's Perspective
  166. Franchise Quarter Back, Franchise Center... Alcon, Genentech, and ACTC!
  167. There is so much expectation for the Gary Mid-Term Presentation... Please hold-off
  168. Novartis' Presentation of its Ocular Strategy and Objectives
  169. BioPharma Playing Hard Ball ... Roche vs. Illumina!
  170. The Abbot Break-up, the Pfizer possible beak-up signals a major wave of change in the Industry
  171. Very Complex JV Conumdrum for ACTC
  172. The Reasons and Whys of the Exclusion/Inclusion Criteria in the SMD and Dry AMD Trials...
  173. The Business and Competitive Advantages of ACTC's hESC's and its combined Patent Portfolio
  174. Finally reached a Conclusion on Why Rabin and the Board wanted to do an RS
  175. Clarifying the meaning of "Liquidity"
  176. Additional Intrepetations of the Rabin comments...
  177. Discovered a new photoreceptor progenitor cell type... What the hell is this!!!????
  178. Alcon's (Novartis) JV with Thrombogenic's is the first move to Dominate Eye Care
  179. ACTC's Mesenchymal Manufacturing Process
  180. #2 Now that is a JV
  181. #1 - Dovetailing, Predictability, and Shrinking the FDA Timeline!
  182. About retinal neural
  183. I am calling another gold for ACTC!
  184. ACTC as a Personal Investment Model
  185. Now that is a JV
  186. Is R/S a possible ruse...
  187. Competitive threats?
  188. Predictability and ACTC as an Investment, and the Current Chess Game
  189. RS is the Correct Strategic Move!
  190. For Long Term Holders Only!
  191. So What have we learned in the last two days?
  192. Other than the AS issue... What is the ONE WORD in the CC that EXCITED a Capitalist Pig?
  193. The AS, the Lanza-Schwartz IMed Presentation, and the RS News this Afternoon...
  194. How much can a Roche or Pfizer spend to insure a leading foothold in Regenerative Medicine?
  195. When the first 6 patients of the SMD 1st Cohorts in the UK and the US has improved vision?
  196. The Hospital's Profit Potential on ACTC's RPE Cells
  197. Our Forward Vision of Combination Treatment and Lanza's Latest Tweets
  198. Roche has the Most to Lose and the Most to Gain!
  199. Anyone with a different Retinal Design and different BM around?
  200. Natural Programming and Natural Driven Market Demand
  201. "Natural Programming" vs. Drugs and Bio-Chemistry
  202. The Foundational Strategy of ACTC
  203. When Does Ceasar get back?
  204. China JV
  205. Major Concern re: our China opening, etc.
  206. Leaving on a Jet Plane in the Morning...
  207. Patents
  208. #2 How much should a combination therapy of NPCs and RPEs Cost?
  209. How much should a combination therapy of NPCs and RPEs Cost?
  210. If takeover we can assume that....
  211. Lanza Selling Stock
  212. Lanza to the Rescue
  213. Lots of Facts from the Lancet Article and Anecdotal Data at the Meeting!
  214. Surprised by Price Action this Week?
  215. Lancet's Article and our JV Valuation!
  216. Lancet's Article did not just validate the RPE's... It validated the Science, Lanza, and ACTC
  217. Looking at ACTC as a Cultural/Religious Shift and a New Ear in Medicine
  218. Begging Ceasar's pardon but.....
  219. The Conjunction of February's AMD Month Activities and ACTC's Events in the Coming Weeks
  220. Understanding ACTC's future Stock Price from a Statistical Standpoint!
  221. First 1000-10000 doses of RPE for AMD
  222. ACTC Revenue
  223. OT: Trials and Errors
  224. The results that Rabin will present....my take
  225. ACT's RPE Cells and China
  226. Hey Guys/Dolls...Enjoy the Weekend...
  227. The China JV Timeline from the October Meeting in China to January 2012
  228. Practical Comparison of hESCs to Autologous and Adult Stem Cells
  229. Question regarding GR's blog
  230. Please Review Bogeyfree's Dec. Post:http://investorstemcell.com/forum/act-main-forum-general-topics-science-press-releases-media/11796.htm
  231. WOW! ACTC will announce one more BOD!
  232. The Human Story between Dr. Schwartz and his Stargardt's Patient
  233. The End Point and Ultimate Objective of ACTC's Ocular Division
  234. If Every Family with Dry AMD in the World...
  235. This is a Celebratory Thread with some Tid Bits and other items of Interest....
  236. The Coming Volatility in Trading of ACTC Stocks...
  237. I have received several questions on the Proxy...
  238. ACTC's Growth Out of the Lab and into the Market... from Start-Up to Revenue Leader!
  239. Repost of conversation with Bio-Digger and others...
  240. #3 The Multiple Paradigm Shifts within ACTC's Patent Portfolio
  241. Okey... So What is happening in the last 2 days?
  242. Very Interesting Data at Moorfields' Website
  243. #2 The Multiple Paradigm Shifts within ACTC's Patent Portfolio
  244. The Multiple Paradigm Shifts within ACTC's Patent Portfolio
  245. ACTC into 1Q/2Q 2012
  246. The Value of One Word in the Coming Peer Reviewed ACTC Article
  247. The Beijing - ACTC Connection
  248. #2 The Biggest among the Big Pharmas...
  249. Stigma of HESC on JV
  250. Major Report With ACT totally missing.

Content Relevant URLs by vBSEO 3.6.0 PL2